Risk scores are widely used in patients with acute coronary syndrome (ACS) prior to
treatment decision-making at different points in time. At initial hospital presentation, risk …

Background Guidelines recommend prasugrel or ticagrelor for acute coronary syndrome
(ACS) patients. However, these P2Y12 inhibitors increase bleeding risk compared to …

Objectives To validate the Global Registry of Acute Coronary Events (GRACE) risk score
and examine the extent and impact of the risk–treatment paradox in contemporary patients …

Aims: To determine the clinical efficacy, adverse events and side-effect dyspnea of CYP3A4*
22 and CYP3A5 expressor status in ticagrelor treated patients. Methods and results …

Abstract Background The cytochrome P450 (CYP) 2C9 enzyme plays a role in the
metabolization of clopidogrel. Carriage of a CYP2C9 loss-of-function (LoF) allele has been …

Diagnostic and treatment strategies for acute coronary syndrome have improved
dramatically over the past few decades, but mortality and recurrent myocardial infarction …

Background Early aspirin withdrawal, also known as P2Y 12-inhibitor monotherapy,
following percutaneous coronary intervention (PCI) for non-ST-segment elevation acute …

This registry assessed the impact of conservative and invasive strategies on major adverse
clinical events (MACE) in elderly patients with non-ST-elevation myocardial infarction …

Objective Patients with acute coronary syndrome (ACS) remain at high risk for recurrent
ischaemic and bleeding events during follow-up. Our study aimed to quantify and compare …

Background Guidelines recommend prasugrel or ticagrelor for acute coronary syndrome
(ACS) patients. However, these P2Y 12 inhibitors increase bleeding risk compared with …